56C8EE15-BEBA-4919-9E57-FA82E90655D8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 133.63994743758212
- age_years
- 24
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.550
- G2M_CHECKPOINT+0.476
- WNT_BETA_CATENIN_SIGNALING+0.463
- TGF_BETA_SIGNALING+0.420
- ANGIOGENESIS+0.399
- HEDGEHOG_SIGNALING+0.389
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.384
- MYC_TARGETS_V1+0.368
- TNFA_SIGNALING_VIA_NFKB+0.366
- MITOTIC_SPINDLE+0.364
Top 10 suppressed
- KRAS_SIGNALING_DN-0.252
- PANCREAS_BETA_CELLS-0.234
- MYOGENESIS-0.229
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.114
- HEME_METABOLISM-0.071
- COAGULATION-0.069
- SPERMATOGENESIS-0.058
- XENOBIOTIC_METABOLISM-0.002
- KRAS_SIGNALING_UP+0.004
- COMPLEMENT+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A280A4AF-0687-40CA-8804-C6173B33E732 | — | — | 0.918 |
| 2 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.917 |
| 3 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.893 |
| 4 | 34229BDA-4BF2-4537-A663-15896F6E269A | — | — | 0.891 |
| 5 | SRR934861 | — | — | 0.885 |
| 6 | SRR934827 | — | — | 0.882 |
| 7 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.875 |
| 8 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.875 |
| 9 | 12B24051-5657-45E8-9C64-5B6A06693471 | — | — | 0.873 |
| 10 | SRR13311157 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.476 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.463 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.399 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.389 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.384 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.368 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.366 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.364 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.348 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.347 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.334 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.331 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.321 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.319 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.313 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.299 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.291 | Inavolisib | — uncovered |